 |
245 Diseases |  |
389 Trials |
|
389 Trials |  |
11400 News |  |
| «12...106107108109110111112113114115116...143144» |
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Gilotrif (afatinib) / Boehringer Ingelheim
Enrollment closed, Combination therapy, EGFR exon 20: AFACET: Afatinib and Cetuximab in Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Positive Non-small-cell Lung Cancer (clinicaltrials.gov) - Dec 11, 2018
P2, N=37, Active, not recruiting, Sponsor: The Netherlands Cancer Institute
Not yet recruiting --> Active, not recruiting
- | Xalkori (crizotinib) / Pfizer, Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P2 trial, Metastases: Molecularly Target Therapy With FORFIRINOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma (clinicaltrials.gov) - Dec 6, 2018
P2, N=150, Recruiting, Sponsor: Shanghai Jiao Tong University School of Medicine
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P2 trial: NCI-2018-02990: Cetuximab in Head and Neck Cancer Patients (clinicaltrials.gov) - Dec 6, 2018
P2, N=36, Not yet recruiting, Sponsor: University of Wisconsin, Madison
- | Keytruda (pembrolizumab) / Merck (MSD)
Trial completion date, PD(L)-1 Biomarker, IO biomarker, Metastases: A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048) (clinicaltrials.gov) - Dec 6, 2018
P3, N=825, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Not yet recruiting --> Active, not recruiting Trial completion date: Jan 2019 --> Jan 2020
- | Bavencio (avelumab) / EMD Serono, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment open, Combination therapy, Metastases: Study of Avelumab and Cetuximab Plus Gemcitabine and Cisplatin in Participants With NSCLC (clinicaltrials.gov) - Dec 5, 2018
P2a, N=40, Recruiting, Sponsor: Merck KGaA, Darmstadt, Germany
Trial completion date: Jan 2019 --> Jan 2020 Not yet recruiting --> Recruiting
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Lynparza (olaparib) / Merck (MSD), AstraZeneca
Trial completion, Combination therapy, Metastases: Study of Olaparib With Radiation Therapy and Cetuximab in Advanced Head and Neck Cancer With Heavy Smoking History (clinicaltrials.gov) - Dec 3, 2018
P1, N=16, Completed, Sponsor: University of Colorado, Denver
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | Bavencio (avelumab) / EMD Serono, Pfizer, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Lynparza (olaparib) / Merck (MSD), AstraZeneca
Journal, BRCA Biomarker, PARP Biomarker, PD(L)-1 Biomarker, IO biomarker: Immunotherapy utilizing the combination of natural killer- and antibody dependent cellular cytotoxicity (ADCC)-mediating agents with poly (ADP-ribose) polymerase (PARP) inhibition. (Pubmed Central) - Dec 1, 2018
Active, not recruiting --> Completed These studies support the combined use of NK- and ADCC-mediating agents with correctly timed PARP inhibition.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Cetuximab and Radiotherapy in Laryngeal Preservanion-Reply. (Pubmed Central) - Nov 30, 2018
These studies support the combined use of NK- and ADCC-mediating agents with correctly timed PARP inhibition. No abstract available
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion date, Trial primary completion date, Metastases: Study of Radiation (RT) Concurrent With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (SCC) (clinicaltrials.gov) - Nov 29, 2018
P2, N=23, Active, not recruiting, Sponsor: University of Michigan Cancer Center
No abstract available Trial completion date: Jul 2018 --> Dec 2018 | Trial primary completion date: Jul 2018 --> Dec 2018
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, P3 data, Journal: Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study. (Pubmed Central) - Nov 28, 2018
P3
Trial completion date: Jul 2018 --> Dec 2018 | Trial primary completion date: Jul 2018 --> Dec 2018 Although this study did not meet its primary endpoints, prespecified subgroup analyses of patients with EGFR FISH-positive squamous-cell carcinoma cancers are encouraging and support continued evaluation of anti-EGFR antibodies in this subpopulation.
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen
Enrollment open, Surgery: SULTAN: Improving SUrgery of Liver Metastases: a Trial of the Arterial Chemotherapy Network (clinicaltrials.gov) - Nov 27, 2018
P2, N=140, Recruiting, Sponsor: UNICANCER
Although this study did not meet its primary endpoints, prespecified subgroup analyses of patients with EGFR FISH-positive squamous-cell carcinoma cancers are encouraging and support continued evaluation of anti-EGFR antibodies in this subpopulation. Active, not recruiting --> Recruiting
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
Journal, HEOR: Impact of drug substitution on cost of care: an example of economic analysis of cetuximab versus panitumumab. (Pubmed Central) - Nov 22, 2018
Panitumumab can lower the cost of care without impacting outcomes in chemo-refractory mCRC settings. This finding provides a strong argument to consider panitumumab in lieu of cetuximab in these patients.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Trial completion date, Trial primary completion date, Metastases: Post-operative Radiation With Cetuximab for Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) - Nov 15, 2018
P2, N=40, Active, not recruiting, Sponsor: University of Cincinnati
This finding provides a strong argument to consider panitumumab in lieu of cetuximab in these patients. Recruiting --> Active, not recruiting | Trial completion date: Oct 2021 --> Oct 2022 | Trial primary completion date: Apr 2017 --> Jan 2019
- | monalizumab (IPH2201) / AstraZeneca, Innate, Imfinzi (durvalumab) / AstraZeneca
Phase classification, Enrollment change, Trial primary completion date, IO biomarker, Metastases: A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors (clinicaltrials.gov) - Nov 13, 2018
P1/2, N=501, Recruiting, Sponsor: MedImmune LLC
Recruiting --> Active, not recruiting | Trial completion date: Oct 2021 --> Oct 2022 | Trial primary completion date: Apr 2017 --> Jan 2019 Phase classification: P1 --> P1/2 | N=262 --> 501 | Trial primary completion date: Feb 2020 --> Oct 2021
- | Xalkori (crizotinib) / Pfizer
Journal: Enhancing the Radiation Response in KRAS Mutant Colorectal Cancers Using the c-Met Inhibitor Crizotinib. (Pubmed Central) - Nov 10, 2018
Inhibition of c-Met with crizotinib effectively sensitizes cetuximab-resistant KRAS mutant colorectal cancer cell lines to radiation. Crizotinib has the potential to improve outcomes in locally advanced rectal cancer patients undergoing chemoradiation.
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Metastases: ITACa: Sequential Treatment Strategy for Metastatic Colorectal Cancer (clinicaltrials.gov) - Nov 9, 2018
P3, N=350, Completed, Sponsor: Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Crizotinib has the potential to improve outcomes in locally advanced rectal cancer patients undergoing chemoradiation. Active, not recruiting --> Completed
- | Keytruda (pembrolizumab) / Merck (MSD)
Enrollment change, Trial completion date, Trial termination, Metastases: Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer (clinicaltrials.gov) - Nov 2, 2018
P1/2, N=16, Terminated, Sponsor: Western Regional Medical Center
N=90 --> 16 | Trial completion date: Dec 2018 --> Aug 2018 | Active, not recruiting --> Terminated; PI no longer at sight. Results not collected
- | Photofrin (porfimer sodium) / Advanz Pharma
New P2 trial, Metastases: Porfimer Sodium Interstitial Photodynamic Therapy With or Without Standard of Care Chemotherapy in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer (clinicaltrials.gov) - Nov 1, 2018
P2, N=82, Not yet recruiting, Sponsor: Roswell Park Cancer Institute
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono, Gilotrif (afatinib) / Boehringer Ingelheim
New P2 trial, Combination therapy, EGFR exon 20: AFACET: Afatinib and Cetuximab in Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Positive Non-small-cell Lung Cancer (clinicaltrials.gov) - Oct 31, 2018
P2, N=37, Not yet recruiting, Sponsor: The Netherlands Cancer Institute
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion date, Metastases: CA225200: PhII ICb With/Without Erbitux in MBC Pts (clinicaltrials.gov) - Oct 25, 2018
P2, N=154, Active, not recruiting, Sponsor: US Oncology Research
Results not collected Trial completion date: Dec 2014 --> Dec 2019
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Trial completion date, Metastases: Phase II Trial of Carboplatin, 5-FU and Cetuximab in Elderly Fit (no Frailty) Patients With Recurrent/Metastatic HNSCC (clinicaltrials.gov) - Oct 25, 2018
P2, N=82, Active, not recruiting, Sponsor: Groupe Oncologie Radiotherapie Tete et Cou
Trial completion date: Dec 2014 --> Dec 2019 Recruiting --> Active, not recruiting | Trial completion date: Dec 2019 --> Aug 2021
- | Bavencio (avelumab) / EMD Serono, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Combination therapy, Metastases: Avelumab and Cetuximab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer - The Phase II AVETUX-CRC Trial. (clinicaltrials.gov) - Oct 25, 2018
P2, N=43, Active, not recruiting, Sponsor: AIO-Studien-gGmbH
Recruiting --> Active, not recruiting | Trial completion date: Dec 2019 --> Aug 2021 Recruiting --> Active, not recruiting
- ||||| abituzumab (EMD 525797) / EMD Serono, SFJ Pharma
New P2 trial, Combination therapy, Metastases: AMELION: Study of Abituzumab in Combination With Cetuximab and FOLFIRI in Patients With Metastatic Colorectal Cancer. (clinicaltrials.gov) - Oct 24, 2018
P2, N=230, Not yet recruiting, Sponsor: SFJ Pharmaceuticals X, LTD.
- | Opdivo (nivolumab) / BMS
Enrollment closed, Combination therapy, Metastases: CheckMate 9TM: Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer (clinicaltrials.gov) - Oct 22, 2018
P3, N=1046, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen
Enrollment open: A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma (clinicaltrials.gov) - Oct 19, 2018
P2, N=30, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment open, Metastases: Concomitant Immune Check Point Inhibitor With Radiochemotherapy in Head And Neck Cancer (clinicaltrials.gov) - Oct 17, 2018
P2, N=50, Recruiting, Sponsor: Kuwait Cancer Control Center
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Bavencio (avelumab) / EMD Serono
Enrollment open, Trial initiation date, Tumor mutational burden, PD(L)-1 Biomarker, Metastases: SAMCO: Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer (clinicaltrials.gov) - Oct 15, 2018
P2, N=118, Recruiting, Sponsor: Federation Francophone de Cancerologie Digestive
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Initiation date: Sep 2017 --> Apr 2018
- | Journal: THE ECSTACY OF GOLD Patent Expirations for Trastuzumab, Bevacizumab, Rituximab, and Cetuximab. (Pubmed Central) - Oct 12, 2018
There are currently only two biosimilars approved in the United States: the trastuzumab biosimilar trastuzumab-dkst (Ogivri) and the bevacizumab biosimilar bevacizumab-awwb (Mvasi). In Europe, SB3, a trastuzumab biosimilar, is approved for use as well as two rituzimab biosimilars, truxima and rixathon.
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly
Trial completion date, Metastases: SWOG S0819: S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer (clinicaltrials.gov) - Oct 12, 2018
P3, N=1546, Active, not recruiting, Sponsor: Southwest Oncology Group
In Europe, SB3, a trastuzumab biosimilar, is approved for use as well as two rituzimab biosimilars, truxima and rixathon. Trial completion date: Aug 2018 --> Aug 2019
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion date, Trial primary completion date, Metastases: IMPACT-CRC: Image Guided Treatment Optimization With Cetuximab for Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Oct 10, 2018
P1/2, N=85, Recruiting, Sponsor: VU University Medical Center
Trial completion date: Aug 2018 --> Aug 2019 Trial completion date: Dec 2017 --> Mar 2019 | Trial primary completion date: Dec 2017 --> Mar 2019
- | Trial completion date, Trial primary completion date, Metastases: QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine (clinicaltrials.gov) - Oct 5, 2018
P1/2, N=382, Recruiting, Sponsor: NantKwest, Inc.
Trial completion date: Dec 2017 --> Mar 2019 | Trial primary completion date: Dec 2017 --> Mar 2019 Trial completion date: Dec 2020 --> Dec 2022 | Trial primary completion date: Dec 2019 --> Jul 2020
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion date, Trial primary completion date: External Beam Radiation Therapy and Cetuximab Followed by Irinotecan and Cetuximab for Children and Young Adults With Newly Diagnosed Diffuse Pontine Tumors and High-Grade Astrocytomas (clinicaltrials.gov) - Oct 4, 2018
P2, N=51, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial completion date: Dec 2020 --> Dec 2022 | Trial primary completion date: Dec 2019 --> Jul 2020 Trial completion date: Nov 2018 --> Nov 2019 | Trial primary completion date: Nov 2018 --> Nov 2019
- |||| feladilimab (GSK3359609) / GSK
New P1/2 trial, New P2 trial, Combination therapy, Metastases: GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors (clinicaltrials.gov) - Oct 2, 2018
P2, N=115, Not yet recruiting, Sponsor: GlaxoSmithKline
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen
New P2 trial: A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma (clinicaltrials.gov) - Oct 2, 2018
P2, N=30, Not yet recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen
Enrollment closed, Surgery: SULTAN: Improving SUrgery of Liver Metastases: a Trial of the Arterial Chemotherapy Network (clinicaltrials.gov) - Oct 2, 2018
P2, N=140, Active, not recruiting, Sponsor: UNICANCER
Trial completion date: Nov 2018 --> Nov 2019 | Trial primary completion date: Nov 2018 --> Nov 2019 Not yet recruiting --> Active, not recruiting
- | fosifloxuridine nafalbenamide (NUC-3373) / NuCana
Enrollment open, Combination therapy: NuTide:302: A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment (clinicaltrials.gov) - Oct 2, 2018
P1, N=62, Recruiting, Sponsor: NuCana plc
Not yet recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono, Imfinzi (durvalumab) / AstraZeneca
New P2 trial, Combination therapy, Metastases: Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Oct 2, 2018
P2, N=36, Recruiting, Sponsor: Trisha Wise-Draper
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Metastases: LERFOX-C: Definitive Chemoradiotherapy and Cetuximab in the Treatment of Locally Advanced Esophageal Cancer (clinicaltrials.gov) - Sep 21, 2018
P2, N=51, Active, not recruiting, Sponsor: Gabriella Alexandersson von D
Not yet recruiting --> Recruiting Trial primary completion date: Apr 2018 --> Dec 2018
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion date, Trial primary completion date, Metastases: Cetuximab Rechallenge Study (clinicaltrials.gov) - Sep 20, 2018
P2, N=17, Active, not recruiting, Sponsor: Chinese University of Hong Kong
Trial primary completion date: Apr 2018 --> Dec 2018 Trial completion date: Jun 2018 --> Dec 2019 | Trial primary completion date: Jun 2018 --> Dec 2018
- || Ibrance (palbociclib) / Pfizer, Bavencio (avelumab) / EMD Serono, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment open, Metastases: Avelumab, Cetuximab, and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Sep 20, 2018
P1, N=24, Recruiting, Sponsor: Kathryn Gold
Trial completion date: Jun 2018 --> Dec 2019 | Trial primary completion date: Jun 2018 --> Dec 2018 Not yet recruiting --> Recruiting
- | napabucasin (BBI608) / Sumitomo Pharma
Enrollment change, Metastases: A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer (clinicaltrials.gov) - Sep 18, 2018
P2, N=203, Active, not recruiting, Sponsor: Boston Biomedical, Inc
Not yet recruiting --> Recruiting N=150 --> 203
- | CPGJ-602 / 3SBio
Trial completion date, Trial primary completion date, Metastases: A Study of Recombinant Anti-EGFR Monoclonal Antibody in Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Sep 17, 2018
P1, N=21, Recruiting, Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
N=150 --> 203 Trial completion date: Aug 2018 --> Nov 2018 | Trial primary completion date: Jun 2018 --> Oct 2018
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Trial primary completion date, Metastases: ARTSCANIII: A Study of Cisplatin Plus Radiotherapy Compared to Cetuximab Plus Radiotherapy in Locally Advanced Head and Neck Cancer. (clinicaltrials.gov) - Sep 14, 2018
P3, N=618, Active, not recruiting, Sponsor: Lund University Hospital
Trial completion date: Aug 2018 --> Nov 2018 | Trial primary completion date: Jun 2018 --> Oct 2018 Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2024 --> Sep 2018
- | prexasertib (ACR-368) / Acrivon Therap
Trial completion date, Trial primary completion date, Combination therapy, Metastases: A Study of Prexasertib (LY2606368) With Chemotherapy and Radiation in Participants With Head and Neck Cancer (clinicaltrials.gov) - Sep 13, 2018
P1b, N=70, Recruiting, Sponsor: Eli Lilly and Company
Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2024 --> Sep 2018 Trial completion date: Oct 2018 --> Jan 2019 | Trial primary completion date: Oct 2018 --> Jan 2019
- | monalizumab (IPH2201) / AstraZeneca, Innate
Enrollment change, Trial completion date, Trial primary completion date, Metastases: IPH2201-203: Study of Monalizumab and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) - Sep 13, 2018
P1b/2, N=100, Recruiting, Sponsor: Innate Pharma
Trial completion date: Oct 2018 --> Jan 2019 | Trial primary completion date: Oct 2018 --> Jan 2019 N=70 --> 100 | Trial completion date: Jun 2019 --> Sep 2020 | Trial primary completion date: Jun 2019 --> Sep 2020
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Cabometyx (cabozantinib tablet) / Exelixis, Ipsen
New P1 trial, Combination therapy, Metastases: Cabozantinib in Combination With Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer (clinicaltrials.gov) - Sep 12, 2018
P1, N=24, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
- | Keytruda (pembrolizumab) / Merck (MSD), Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P2 trial, Metastases: I-Tackle: Immunotherapy +/- EGFR Inhibitor In Advanced/Metastatic cSCC: Tackling Primary And Secondary Resistance (clinicaltrials.gov) - Sep 11, 2018
P2, N=43, Not yet recruiting, Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Trial termination, Surgery, Metastases: COMBATAC: Combined Anticancer Treatment of Advanced Colon Cancer (clinicaltrials.gov) - Sep 5, 2018
P2, N=26, Terminated, Sponsor: University of Regensburg
N=70 --> 100 | Trial completion date: Jun 2019 --> Sep 2020 | Trial primary completion date: Jun 2019 --> Sep 2020 N=60 --> 26 | Active, not recruiting --> Terminated; Slow recruitment.
- | Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
Trial completion date, Metastases: Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer (clinicaltrials.gov) - Sep 5, 2018
P1/2, N=150, Active, not recruiting, Sponsor: Array BioPharma
N=60 --> 26 | Active, not recruiting --> Terminated; Slow recruitment. Trial completion date: Jul 2018 --> Jul 2019
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
Trial completion: S1013: Validation of Cancer Questionnaire for Skin Toxicities in Patients With Colorectal Cancer or Lung Cancer Receiving Cetuximab, Panitumumab, or Erlotinib Hydrochloride (clinicaltrials.gov) - Sep 1, 2018
P=N/A, N=146, Completed, Sponsor: Southwest Oncology Group
Trial completion date: Jul 2018 --> Jul 2019 Active, not recruiting --> Completed